Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting
Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer
PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault as Chairman and board member as of March 2022. With extensive experience over 35 years in leadership roles at leading companies across the biotech and pharmaceutical sector, Mr. Legault will be a key part of the team as Egle deploys its first-in-class technology platforms to construct a drug pipeline of novel immunotherapies targeting suppressor regulatory T cells (Tregs).
The Seattle-based biotech originates in the lab of Mark Davis, Ph.D., director of the Stanford Institute for Immunology, Transplantation and Infection. Davis' work focuses on how CD8 T regulatory cells play a central part in the surveillance, recognition and elimination of certain immune cells that cause autoimmune and inflammatory disease, Mozart said Tuesday.
PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has completed a €40M ($46.4M) Series A financing. The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund. Fund+, Bioqube Ventures and Takeda Ventures, Inc. also participated in this round.
A new World Health Organization (WHO) road map for neglected tropical diseases (NTDs) proposes ambitious targets and innovative approaches to tackle 20 diseases that affect more than a billion mainly poor people and which thrive in areas where access to quality health services, clean water and sanitation is scarce.
PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”). In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”). In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.